The goal of this natural history study is to capture the natural history of Duchenne Muscular Dystrophy (DMD) in children and adults in the United Kingdom. Children and adults with DMD will be invited to join. The primary objective of the study is to collect longitudinal data on motor and respiratory function in DMD patients from childhood to adulthood. The secondary objectives of the study include collection of longitudinal data on other aspects of natural history on DMD, including respiratory, cardiac and endocrine complications, neurodiversity (cognitive impairment, neuro-behavioural disorders such as ADHD and autism), changes to bone density and occurrence of fractures, changes to puberty, incidence of scoliosis, unplanned hospital admissions, and quality of life. The study will also collect information on ethnicity. Participants will attend an annual or bi-annual neuromuscular clinic, and will have a series of assessments and questionnaires with the study team. These include: key medical data, physiotherapy data, respiratory assessments, Quality of Life questionnaires, and DMD questionnaires. Following assessments and questionnaire completion, data is input into the study's tailor-made National Neuromuscular Database.
This study will make use of the existing NorthStar network to collect a wider range of clinically relevant data from paediatric and adult DMD patients, to describe more completely the natural history of the disease in different domains and across different life stages and disease phases. Data will be collected using assessment techniques and outcome measures appropriate to the major phases of the disease, and which are in some cases not currently part of the standard of care for DMD in the UK. The National Neuromuscular Database will continue to be used to collect and store these data. This study will allow the network to continue to describe the current natural history in DMD prospectively, with more robust subject ascertainment and completeness. This will help meet the current need for contemporary natural history data for the evaluation of new therapies, and further research in DMD.
Study Type
OBSERVATIONAL
Enrollment
300
Aberdeen, NHS Grampian
Aberdeen, United Kingdom
Belfast Health and Social Care Trust
Belfast, United Kingdom
Birmingham Children's Hospital
Birmingham, United Kingdom
Birmingham Community Healthcare NHS Foundation Trust
Birmingham, United Kingdom
Birmingham Heartlands Hospital
Birmingham, United Kingdom
University Hospitals Bristol and Weston
Bristol, United Kingdom
Cambridge University Hospitals
Cambridge, United Kingdom
Cardiff and Vale University Health Board
Cardiff, United Kingdom
NHS Dundee - Tayside
Dundee, United Kingdom
NHS Greater Glasgow and Clyde
Glasgow, United Kingdom
...and 16 more locations
Longitudinal data on motor function in Duchenne Muscular Dystrophy (DMD) patients from the childhood to the adult phases of life
Measure: NorthStar Ambulatory Assessment (NSAA). a scale from 0 (unable), 1 (completes independently but with modifications), and 2 (completed without compensation). Total score 0 - 34 with a higher score denoting a higher level of function.
Time frame: From enrolment to the end of the study, across 18 months
Longitudinal data on quality of life in childhood and adult patients.
Measure: Duchenne Muscular Dystrophy Quality of Life Measure (DMD-QoL). The DMD-QoL has a hierarchical (or 'higher-order') factor structure, with 3 lower-order factors (physical, social, and psychological) and 1 higher-order factor (overall quality of life \[QoL\], comprised of the 3 lower-order factors). Higher scores represent a more positive QoL (overall or within each subscale).
Time frame: From enrolment to the end of the study, across 18 months
Longitudinal data on quality of life in childhood and adult patients.
Measure: The Quality of Life in Genetic Neuromuscular Disease Questionnaire (QoL-gNMD). The QoL-gNMD domain is measured on a T score metric i.e. a normal distribution with a mean of 50 and a standard deviation of 10. High values represent good quality of life.
Time frame: From enrolment to the end of the study, across 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.